Skip to main content
. 2021 Dec 17;23(2):51. doi: 10.3892/ol.2021.13169

Figure 8.

Figure 8.

KHYG-1 cell direct cytotoxicity against AML cells with FLT3 mutations and ADCC of primary NK cells against MOLM-13 and MV-4-11 cells are enhanced under FLT3 inhibition. γδ T cell cytotoxicity against AML cells with FLT3 mutations was not enhanced under FLT3 inhibition. (A) NK cell direct cytotoxicity assay. Target cells (MOLM-13 and MV-4-11) were exposed to quizartinib or DMSO for 48 h before coculture with KHYG-1 cells at various E/T ratios (0–30). (B) ADCC assay of daratumumab. Target cells (MOLM-13 and MV-4-11) were exposed to quizartinib or DMSO for 48 h before coculture with KHYG-1/CD16 cells. (C) γδ T cell direct cytotoxicity assay. Target cells (MOLM-13 and MV-4-11) were exposed to quizartinib or DMSO for 48 h before coculture with γδ T cells at various E/T ratios (0–10). All experiments were repeated thrice. Error bars represent the SD. Data were statistically analyzed using a multiple linear regression model. *P<0.05; **P<0.01. ADCC, antibody-dependent cellular cytotoxicity; AML, acute myeloid leukemia; E/T, effector/tumor; FLT3, FMS-like tyrosine kinase 3; NK, natural killer; NS, no significant difference.